SAFE KIDS Act

Download PDF
Bill ID: 119/hr/7040
Last Updated: June 3, 2026

Sponsored by

Rep. Moore, Blake D. [R-UT-1]

ID: M001213

Follow the money

The bill

SAFE KIDS Act

HR. 7040, 119th Congress.

The sponsor

Rep. Moore, Blake D. [R-UT-1]

Every bill has someone who introduced it. That name is where the paper trail starts.

The money

$99,500 raised

24 itemised contributions to this sponsor, pulled from FEC filings.

The alignment

55% match to Project 2025

This bill's text tracks the "Department of Health and Human Services" section, p. 533-535 of the Mandate for Leadership.

Bill's Journey to Becoming a Law

Track this bill's progress through the legislative process

Latest Action

Sponsor introductory remarks on measure. (CR H1161-1162)

January 20, 2026

Introduced

📍 Current Status

Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.

🏛️

Committee Review

🗳️

Floor Action

✅

Passed House

🏛️

Senate Review

🎉

Passed Congress

🖊️

Presidential Action

⚖️

Became Law

📚 How does a bill become a law?

1. Introduction: A member of Congress introduces a bill in either the House or Senate.

2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.

3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.

4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.

5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.

6. Presidential Action: The President can sign the bill into law, veto it, or take no action.

7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!

Bill Summary

Another brilliant example of legislative theater, courtesy of the SAFE KIDS Act (HR 7040). Let's dissect this farce and expose the real motivations behind it.

**Main Purpose & Objectives:** The bill claims to prevent citizens of foreign adversarial nations from exploiting commercial surrogacy laws in the United States. How noble. In reality, it's a thinly veiled attempt to restrict reproductive rights and score cheap political points.

**Key Provisions & Changes to Existing Law:**

* Invalidates surrogate parentage contracts between prospective parents from foreign entities of concern and a surrogate mother in the United States. * Imposes criminal penalties on surrogacy brokers who commercially facilitate such invalid agreements. * Defines "foreign entity of concern" as any foreign nation listed under section 4872(f)(2) of title 10, United States Code (read: China, Russia, and other boogeymen).

**Affected Parties & Stakeholders:**

* Surrogate mothers in the United States who might be exploited by foreign nationals (or so the bill claims). * Prospective parents from foreign entities of concern who want to use surrogacy services in the United States. * Surrogacy brokers who facilitate these agreements (and will now face penalties).

**Potential Impact & Implications:**

* This bill is a solution in search of a problem. The number of cases involving foreign nationals exploiting surrogate mothers in the United States is likely minuscule compared to other reproductive health issues. * It's a thinly veiled attempt to restrict reproductive rights, particularly for low-income women who might consider surrogacy as an option. * The bill's language is so broad that it could be used to target any foreign national seeking surrogacy services in the United States, not just those from "adversarial nations." * It will drive the surrogacy industry underground, making it more difficult for women to access safe and regulated services.

In short, this bill is a classic case of legislative grandstanding. It's a cynical attempt to score points with conservative voters while doing nothing to address the real issues facing reproductive health in the United States. The sponsors of this bill should be ashamed of themselves for peddling such obvious nonsense.

Generated using Llama 3.1 70B (Dr. Haus personality)

💰 Campaign Finance Network

Rep. Moore, Blake D. [R-UT-1]

Congress 119 • 2024 Election Cycle

Total Contributions
$99,500
21 donors
PACs
$0
Organizations
$18,200
Committees
$0
Individuals
$81,300

No PAC contributions found

1
JLS HOLDINGS LLC
1 transaction
$9,900
2
THE CHICKASAW NATION
1 transaction
$3,300
3
HEMMCO LLC
1 transaction
$2,500
4
R & O CONSTRUCTION
1 transaction
$2,500

No committee contributions found

1
MOORE, BRENT
2 transactions
$12,000
2
LOCKWOOD, DAVID
3 transactions
$9,900
3
PARKER, ALEXANDRA
1 transaction
$6,600
4
PARKER, SEAN
1 transaction
$6,600
5
KAUFMAN, TRENT
1 transaction
$6,600
6
CHANG, JASON
1 transaction
$3,300
7
REHNERT, GEOFFREY
1 transaction
$3,300
8
HALL, JEREMY
1 transaction
$3,300
9
FORREST, CHAD B
1 transaction
$3,300
10
WALKER, TODD
1 transaction
$3,300
11
BAILEY, BRETT M.
1 transaction
$3,300
12
BAILEY, KIM
1 transaction
$3,300
13
FORREST, SHANNON
1 transaction
$3,300
14
DUHAMEL, WILLIAM F.
1 transaction
$3,300
15
SMITH, BURR
1 transaction
$3,300
16
EDWARDS, TAMMY
1 transaction
$3,300
17
FORREST, CLINT
1 transaction
$3,300

Cosponsors & Their Campaign Finance

This bill has 10 cosponsors. Below are their top campaign contributors.

Rep. Moolenaar, John R. [R-MI-2]

ID: M001194

Top Contributors

10

1
MATCH-E-BE-NASH-SHE-WISH BAND POTTAWATOMI INDIANS
OrganizationSHELBYVILLE, MI
$3,300
Aug 30, 2023
2
PECHANGA BAND OF INDIANS
OrganizationTEMECULA, CA
$3,300
Aug 30, 2023
3
POKAGON BAND OF POTAWATOMI INDIANS
OrganizationDOWAGIAC, MI
$3,300
Aug 30, 2023
4
SAGINAW CHIPPEWA INDIAN TRIBE TRIBAL OPERATIONS
OrganizationMOUNT PLEASANT, MI
$3,300
Sep 30, 2023
5
SHINGLE SPRINGS BAND OF MIWOK INDIANS
OrganizationSHINGLE SPRINGS, CA
$3,300
Sep 30, 2023
6
NOTTAWASEPPI HURON BAND OF THE POTAWATOMI
OrganizationFULTON, MI
$3,300
Mar 12, 2024
7
SHAKOPEE MDEWAKANTON SIOUX COMMUNITY
OrganizationPRIOR LAKE, MN
$3,300
Jun 20, 2024
8
SAULT STE. MARIE TRIBE CHIPPEWA INDIANS
OrganizationSAULT SAINTE MARIE, MI
$2,900
Dec 19, 2023
9
SAN MANUEL BAND OF MISSION INDIANS
OrganizationLOS ANGELES, CA
$2,500
Mar 4, 2024
10
SHINGLE SPRINGS BAND OF MIWOK INDIANS
OrganizationSHINGLE SPRINGS, CA
$2,500
Sep 30, 2024

Rep. Kiggans, Jennifer A. [R-VA-2]

ID: K000399

Top Contributors

10

1
AIPAC- EARMARKS
PACWASHINGTON, DC
$2,000
Oct 22, 2024
2
PEAKE FOR SENATE
COMLYNCHBURG, VA
$500
Jan 9, 2024
3
PEAKE FOR SENATE
COMLYNCHBURG, VA
$250
Jan 9, 2024
4
KEHOE, MICHAEL
KINSALE MGMT INC • CEO
IndividualRICHMOND, VA
$13,200
Jun 8, 2023
5
MITCHUM, ELZA
C & M INDUSTRIES • PRESIDENT
IndividualCHESAPEAKE, VA
$6,600
Oct 18, 2023
6
SILVERMAN, JEFFREY
RETIRED • RETIRED
IndividualMIAMI BEACH, FL
$6,600
Oct 17, 2023
7
PERRY, J DOUGLAS
RETIRED • RETIRED
IndividualNORFOLK, VA
$6,600
Nov 6, 2023
8
WEEKLEY, RICHARD
SELF EMPLOYED • REAL ESTATE DEVELOPER
IndividualHOUSTON, TX
$6,600
Nov 8, 2023
9
GILLIAM, MARVIN
RETIRED • RETIRED
IndividualBRISTOL, VA
$6,600
Mar 30, 2024
10
BOHANNON, DAVID
LONDON BRIDGE TRADING INC. • PRESIDENT
IndividualVIRGINIA BEACH, VA
$6,600
May 23, 2024

Rep. Aderholt, Robert B. [R-AL-4]

ID: A000055

Top Contributors

10

1
CHALMERS, ADAMS, BACKER & KAUFMAN LLC
OrganizationJOHNS CREEK, GA
$2,900
Mar 7, 2023
2
IMPACT JOURNALS
OrganizationORCHARD PARK, NY
$1,200
Jun 4, 2023
3
SUIT, LLC
OrganizationATTALLA, AL
$500
Jun 10, 2023
4
ROBIN, CRAIG A.
EO SOLUTIONS • CEO
IndividualALBUQUERQUE, NM
$6,600
Nov 13, 2023
5
HOKR, BRETT H.
EO SOLUTIONS • CTO
IndividualHUNTSVILLE, AL
$6,600
Nov 13, 2023
6
LESSMANN, KURT M.
TRIDEUM • CTO
IndividualMADISON, AL
$6,600
Oct 2, 2023
7
KHALILI, KAVEH
EO SOLUTIONS • COO
IndividualBOULDER CITY, NV
$6,600
Nov 13, 2023
8
BUFFALOE, STEPHANIE
HOME INSTEAD TUSCALOOSA • OWNER
IndividualTUSCALOOSA, AL
$6,600
Nov 15, 2023
9
COLLAZO, FRANCISCO JOSE
COLSA CORP • PRESIDENT/CEO
IndividualHUNTSVILLE, AL
$6,600
Oct 2, 2023
10
HUNT, RAY L.
HUNT CONSOLIDATED INC. • PRESIDENT
IndividualDALLAS, TX
$6,600
Feb 21, 2024

Rep. Dunn, Neal P. [R-FL-2]

ID: D000628

Top Contributors

10

1
POARCH BAND OF CREEK INDIANS
OrganizationATMORE, AL
$3,300
Aug 19, 2024
2
SHOOTS, KYLE MR.
SYSTEM SERVICE & ENGINEERING INC • PRESIDENT
IndividualPANAMA CITY, FL
$10,000
Jun 18, 2024
3
CAMAISA, ALLAN
CALIDI BIO • CHAIRMAN AND CEO
IndividualRANCHO SANTA FE, CA
$6,600
Apr 12, 2023
4
PERGOLINI, WILLIAM
AUDIENTIS LLC • PRESIDENT
IndividualROSWELL, GA
$5,000
Sep 2, 2023
5
PERGOLINI, WILLIAM
AUDIENTIS LLC • PRESIDENT
IndividualROSWELL, GA
$5,000
Sep 2, 2023
6
SCHWARZMAN, CHRISTINE
RETIRED • RETIRED
IndividualNEW YORK, NY
$5,000
Jun 5, 2024
7
SCHWARZMAN, STEPHEN
BLACKSTONE • CEO AND CHAIRMAN
IndividualNEW YORK, NY
$5,000
May 31, 2024
8
D'ISERNIA, MIRIAM A. MS
HOMEMAKER • HOMEMAKER
IndividualPANAMA CITY BEACH, FL
$3,400
Sep 29, 2023
9
PERGOLINI, WILLIAM
IndividualROSWELL, GA
$3,400
Sep 29, 2023
10
SHOOTS, CHRISTINA MRS.
IndividualPANAMA CITY, FL
$3,400
Jun 18, 2024

Rep. Moran, Nathaniel [R-TX-1]

ID: M001224

Top Contributors

10

1
PELTIER, PATRICK
PELTIER AUTO GROUP • VICE PRESIDENT
IndividualTYLER, TX
$9,900
Jan 31, 2024
2
PELTIER, PATRICK
IndividualTYLER, TX
$6,600
Feb 22, 2024
3
MARSHALL, MATTHEW
DRAKE • REAL ESTATE
IndividualTYLER, TX
$6,600
Aug 22, 2024
4
MARSHALL, MATTHEW
DRAKE • REAL ESTATE
IndividualTYLER, TX
$6,600
Aug 22, 2024
5
ANDERSON, RICHARD M.
PAFFORD EMS • 911 PROFESSIONAL
IndividualMARSHALL, TX
$5,000
Apr 15, 2024
6
LEATHERWOOD, HARRY
SELF • SELF
IndividualTYLER, TX
$5,000
Sep 23, 2024
7
STOVALL, SCOTT
IndividualTROUP, TX
$3,300
Jan 18, 2024
8
PELTIER, MIKAH ANN
COMMUNITY VOLUNTEER • COMMUNITY VOLUNTEER
IndividualTYLER, TX
$3,300
Jan 31, 2024
9
PELTIER, PATRICK
PELTIER AUTO GROUP • VICE PRESIDENT
IndividualTYLER, TX
$3,300
Jan 31, 2024
10
STEVENSON, DAVID L
CUSTOM COMMODITIES TRANSPORT • OWNER
IndividualDIANA, TX
$3,300
Feb 1, 2024

Rep. Gosar, Paul A. [R-AZ-9]

ID: G000565

Top Contributors

10

1
COLORADO RIVER INDIANS TRIBES
OrganizationPARKER, AZ
$2,000
Sep 21, 2023
2
COLORADO RIVER INDIANS TRIBES
OrganizationPARKER, AZ
$1,000
Jun 29, 2024
3
MORONGO BAND OF MISSION INDIANS
OrganizationBANNING, CA
$1,000
Jul 19, 2023
4
SCHIRMER, SCOTT
M3 COMP • EXECUTIVE
IndividualSCOTTSDALE, AZ
$5,000
May 20, 2024
5
SMITH, RYAN
SELF EMPLOYED • ENTREPRENEUR
IndividualSCOTTSDALE, AZ
$5,000
May 20, 2024
6
SCHIRMER, SCOTT
IndividualSCOTTSDALE, AZ
$5,000
Jun 5, 2024
7
SMITH, RYAN
IndividualSCOTTSDALE, AZ
$5,000
Jun 5, 2024
8
TAPIA, DONALD
RETIRED • RETIRED
IndividualPARADISE VALLEY, AZ
$5,000
Aug 29, 2024
9
TAPIA, DONALD
IndividualPARADISE VALLEY, AZ
$5,000
Sep 9, 2024
10
O'KEEFFE, WILLIAM
SAFTI • PRESIDENT
IndividualSAN FRANCISCO, CA
$5,000
Oct 23, 2024

Rep. Harshbarger, Diana [R-TN-1]

ID: H001086

Top Contributors

10

1
BROWN, NANCY I.
RETIRED • RETIRED
IndividualPALM BEACH, FL
$6,600
Mar 7, 2024
2
NANCY, BROWN
RETIRED • RETIRED
IndividualPALM BEACH, FL
$6,600
Mar 31, 2024
3
GREGORY, LUCINDA
RETIRED • RETIRED
IndividualPINEY FLATS, TN
$6,600
May 21, 2024
4
BANKE, BARBARA R
IndividualGEYSERVILLE, CA
$6,600
Nov 30, 2023
5
MORRIS, GLENN
IndividualSTUART, FL
$6,600
Sep 30, 2024
6
TAYLOR, MARGARETTA J MISS
RETIRED • RETIRED
IndividualNEW YORK, NY
$6,600
Jul 16, 2024
7
EGER, MORDECHI
HLU SALES INC • OWNER
IndividualAIRMONT, NY
$5,000
Dec 28, 2023
8
BORDEAU, BRAD
BORDEAU METALS • CEO
IndividualDICKSON, TN
$5,000
Sep 11, 2024
9
BENTZ, KAREN
IndividualGATLINBURG, TN
$5,000
Sep 30, 2023
10
MOUNTAIN, MONICA
RETIRED • RETIRED
IndividualNEW TAZEWELL, TN
$3,600
Sep 30, 2024

Rep. McCormick, Richard [R-GA-7]

ID: M001218

Top Contributors

10

1
OGLESBY, CHARLES
RETIRED • RETIRED
IndividualSUWANEE, GA
$10,000
Jan 18, 2024
2
OGLESBY, CHARLES
IndividualSUWANEE, GA
$10,000
Jan 22, 2024
3
HAMILTON, ANNE
THORNBRIAR CAPITAL LLC • BUSINESS OWNER
IndividualCUMMING, GA
$10,000
Feb 13, 2023
4
VERMA, VIKAS
RETIRED • RETIRED
IndividualATLANTA, GA
$6,600
Oct 28, 2024
5
KLINGENSTEIN, THOMAS
COHEN KLINGENSTEIN • INVESTMENT ADVISOR
IndividualNEW YORK, NY
$6,600
Oct 28, 2023
6
LUKE, DEBRA
RETIRED • RETIRED
IndividualPHOENIX, AZ
$6,600
Feb 6, 2024
7
BATMASIAN, JAMES H
INVESTMENTS LIMITED • OWNER
IndividualBOCA RATON, FL
$6,600
May 25, 2023
8
KOLLAR, CLINT
SIXTH STREET PARTNERS • INVESTOR
IndividualSAN FRANCISCO, CA
$6,600
May 28, 2023
9
KOLLAR, HEATHER
SELF • MOTHER
IndividualSAN FRANCISCO, CA
$6,600
May 28, 2023
10
STEBBINS, ROBERT
WILLKIE FARR GALLAGHER • ATTORNEY
IndividualNEW YORK, NY
$6,600
Apr 1, 2023

Rep. Rulli, Michael A. [R-OH-6]

ID: R000619

Top Contributors

10

1
10SIX CONSUTLING
OrganizationHUDSON, WI
$10,000
Mar 29, 2024
2
10SIX CONSUTLING
OrganizationHUDSON, WI
$10,000
Mar 31, 2024
3
10SIX CONSUTLING
OrganizationHUDSON, WI
$6,000
Mar 28, 2024
4
10SIX CONSUTLING
OrganizationHUDSON, WI
$6,000
Mar 31, 2024
5
BUCKEYE JUNCTION LLC
OrganizationCOLUMBUS, OH
$1,000
Dec 20, 2023
6
LEHMAN PUBLIC POLICY LLC
OrganizationNEWARK, OH
$500
Dec 12, 2023
7
NELSON GOVERNMENT STRATEGIES LLC
OrganizationCOLUMBUS, OH
$350
Dec 12, 2023
8
SMITH, GREGORY B. MR. SR.
COMPCO • CHAIRMAN OF THE BOARD
IndividualCOLUMBIANA, OH
$6,600
Mar 11, 2024
9
MILLER, SAMUEL
TRUMBULL INDUSTRIES • OWNER
IndividualYOUNGSTOWN, OH
$6,600
Mar 15, 2024
10
SMITH, GREGORY B. MR. SR.
IndividualCOLUMBIANA, OH
$6,600
Mar 14, 2024

Rep. McDowell, Addison P. [R-NC-6]

ID: M001240

Top Contributors

10

1
FLOW, MEGHAN
HOMEMAKER • HOMEMAKER
IndividualLEWISVILLE, NC
$6,600
Mar 1, 2024
2
FLOW, MEGHAN
IndividualLEWISVILLE, NC
$6,600
Feb 29, 2024
3
KING, SEBASTIAN
SELF EMPLOYED • CONSULTANT
IndividualPFAFFTOWN, NC
$3,435
May 28, 2024
4
JOHNSON, BRIAN
IndividualALEXANDRIA, VA
$3,300
Oct 23, 2024
5
BROWN, THOMAS
MINDSET • PARTNER
IndividualCHEVY CHASE, MD
$3,300
Nov 5, 2024
6
TOWNSEND, JOHN
PAY TEL COMMUNICATIONS • OWNER
IndividualKERNERSVILLE, NC
$3,300
Oct 20, 2024
7
BRAUER, CAMILLA
RETIRED • RETIRED
IndividualBRIDGETON, MO
$3,300
Sep 20, 2024
8
BRAUER, STEPHEN
HUNTER ENGINEERING • CHAIRMAN
IndividualBRIDGETON, MO
$3,300
Sep 18, 2024
9
SHAHEEN, LAWRENCE
SELF-EMPLOYED • ATTORNEY
IndividualCHARLOTTE, NC
$3,300
Jul 16, 2024
10
CANNON, CRAIG
KILPATRICK TOWNSEND & STOCKTON • ATTORNEY
IndividualWINSTON SALEM, NC
$3,300
Dec 31, 2024

Donor Network - Rep. Moore, Blake D. [R-UT-1]

PACs
Organizations
Individuals
Politicians

Hub layout: Politicians in center, donors arranged by type in rings around them.

Loading...

Showing 60 nodes and 39 connections (46 secondary connections hidden)

Total contributions: $159,750

Top Donors - Rep. Moore, Blake D. [R-UT-1]

Showing top 21 donors by contribution amount

4 Orgs17 Individuals

Project 2025 Policy Matches

This bill shows semantic similarity to the following sections of the Project 2025 policy document.AI-enhanced analysis provides detailed alignment ratings.

Department of Health and Human Services

Weak
Vector: 64%
Pages: 533-535AI Enhanced

AI Analysis:

"The SAFE KIDS Act focuses on restricting foreign nationals from engaging in U.S. surrogacy arrangements due to national security and exploitation concerns, while the Project 2025 HHS excerpts emphasize healthcare access, civil rights protections, reproductive health services, and family planning—particularly around gender-affirming care, disability non-discrimination, and maternal health. There is minimal thematic overlap, as the bill does not address healthcare delivery, civil rights enforcemen"

Key themes:reproductive healthfamily planningmaternal health

— 501 — Department of Health and Human Services 54. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, Office of Civil Rights, and Office of the Secretary, “Special Responsibilities of Medicare Hospitals in Emergency Cases and Discrimination on the Basis of Disability in Critical Health and Human Service Programs or Activities,” draft of Proposed Rule, January 14, 2021, https://www.hhs.gov/sites/default/files/infants-nprm.pdf (accessed March 17, 2023). 55. H.R. 26, Born-Alive Abortion Survivors Protection Act, 118th Congress, introduced January 9, 2023, https:// www.congress.gov/118/bills/hr26/BILLS-118hr26pcs.pdf (accessed March 17, 2023). 56. H.R. 7, No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2023, 118th Congress, introduced January 9, 2023, https://www.congress.gov/118/bills/hr7/BILLS-118hr7ih.pdf (accessed March 17, 2023). 57. S. 401, Conscience Protection Act of 2021, 117th Congress, introduced February 24, 2021, https://www.congress. gov/117/bills/s401/BILLS-117s401is.pdf (accessed March 17, 2023). 58. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, and Office of the Secretary, “Nondiscrimination in Health Programs and Activities,” Notice of Proposed Rulemaking; Notice of Tribal Consultation, Federal Register, Vol. 87, No. 149 (August 4, 2022), pp. 47824–47920, https://www.govinfo. gov/content/pkg/FR-2022-08-04/pdf/2022-16217.pdf (accessed March 17, 2023). 59. Ibid., p. 47916. 60. The regulation was not finalized before the end of the Administration. U.S. Department of Agriculture, Food and Nutrition Services, “Revision of Categorical Eligibility in the Supplemental Nutrition Assistance Program (SNAP),” Proposed Rule, Federal Register, Vol. 84, No. 142 (July 24, 2019), pp. 35570–55581, https:// www.federalregister.gov/documents/2019/07/24/2019-15670/revision-of-categorical-eligibility-in-the- supplemental-nutrition-assistance-program-snap (accessed March 17, 2023). 61. 45 Code of Federal Regulations § 75.300(c) and (d), https://www.ecfr.gov/current/title-45/subtitle-A/ subchapter-A/part-75/subpart-D/subject-group-ECFR911e5e1a30bfbcb/section-75.300 (accessed March 17, 2023). 62. H.R. 1750, Child Welfare Provider Inclusion Act of 2021, 117th Congress, introduced March 10, 2021, https:// www.congress.gov/117/bills/hr1750/BILLS-117hr1750ih.pdf (accessed March 17, 2023), and S. 656, Child Welfare Provider Inclusion Act of 2021, 117th Congress, introduced March 10, 2021, https://www.congress.gov/117/bills/ s656/BILLS-117s656is.pdf (accessed March 17, 2023). 63. S. 3949, Trafficking Victims Protection Reauthorization Act of 2022, Public Law No. 117-348, 117th Congress, January 25, 2023, https://www.congress.gov/117/plaws/publ348/PLAW-117publ348.pdf (accessed March 17, 2023). 64. Kelsey Y. Santamaria, “Child Migrants at the Border: The Flores Settlement Agreement and Other Legal Developments,” Congressional Research Service In Focus No. IF11799, April 1, 2021, https://crsreports.congress. gov/product/pdf/IF/IF11799 (accessed March 17, 2023). 65. Report, Building a Happy Home: Marriage Education as a Tool to Strengthen Families, Social Capital Project Report No. 1-22, March 2022, p. 17, https://www.jec.senate.gov/public/_cache/files/3d102525-6f0d-48ed- 92f4-d71edd468ad6/building-a-happy-home.pdf (accessed March 17, 2023). The cover of the report reflects that the Social Capital Project is “[a] project of the Joint Economic Committee – Republicans.” 66. See, for example, Alan J. Hawkins, “Are Federally Supported Relationship Education Programs for Lower-Income Individuals and Couples Working? A Review of Evaluation Research,” American Enterprise Institute, September 2019, https://www. congress.gov/117/plaws/publ228/PLAW-117publ228.pdf (accessed March 17, 2023). 67. H.R. 8404, Respect for Marriage Act, Public Law No. 117-228, 117th Congress, December 13, 2022, https://www. congress.gov/117/plaws/publ228/PLAW-117publ228.pdf (accessed March 17, 2023). 68. Madison Marino, “Over 1,000 Safety Violations Mar Head Start. Children Deserve Better,” Heritage Foundation Commentary, November 10, 2022, https://www.heritage.org/education/commentary/over-1000-safety- violations-mar-head-start-children-deserve-better. 69. American Hospital Association v. Becerra, 596 U.S. ___ (2022), https://www.supremecourt.gov/ opinions/21pdf/20-1114_09m1.pdf (accessed March 17, 2023). 70. U.S. Department of the Treasury, Internal Revenue Service; U.S. Department of Labor, Employee Benefits Security Administration; and U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, “Coverage of Certain Preventive Services Under the Affordable Care Act,” Notice of Proposed Rulemaking, Federal Register, Vol. 88, No. 22 (February 2, 2023), pp. 7236–7281, https://www. govinfo.gov/content/pkg/FR-2023-02-02/pdf/2023-01981.pdf (accessed March 17, 2023). — 502 — Mandate for Leadership: The Conservative Promise 71. 42 U.S. Code § 238n, https://www.law.cornell.edu/uscode/text/42/238n (accessed March 17, 2023). 72. U.S. Department of Health and Human Services, Health Resources and Services Administration, “Early Childhood Health,” last reviewed October 2022, https://mchb.hrsa.gov/programs-impact/focus-areas/early- childhood-health (accessed March 17, 2023). 73. American Pregnancy Association, “Having a Doula—What Are the Benefits?” https://americanpregnancy. org/healthy-pregnancy/labor-and-birth/having-a-doula/#:~:text=Other%20studies%20have%20shown%20 that%20having%20a%20doula,massage%20to%20reduce%20stress%20and%20anxiety%20during%20labor (accessed March 17, 2023). 74. S. 2372, VA MISSION [Maintaining Internal Systems and Strengthening Integrated Outside Networks] Act of 2018, Public Law No. 115-182, 115th Congress, June 6, 2018, https://www.congress.gov/115/plaws/publ182/ PLAW-115publ182.pdf (accessed March 17, 2023). 75. U.S. Department of Health and Human Services, “Securing Updated and Necessary Statutory Evaluations Timely,” Final Rule, Federal Register, Vol. 86, No. 11 (January 19, 2021), pp. 5694–5764, https://www.govinfo. gov/content/pkg/FR-2021-01-19/pdf/2021-00597.pdf (accessed March 22, 2023). 76. U.S. Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health, “Compliance with Statutory Program Integrity Requirements,” Final Rule, Federal Register, Vol. 84, No. 42 (March 4, 2029), pp. 7714–7791, https://www.govinfo.gov/content/pkg/FR-2019-03-04/pdf/2019-03461.pdf (accessed March 18, 2023). 77. U.S. Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health, “Ensuring Access to Equitable, Affordable, Client-Centered, Quality Family Planning Services,” Final Rule, Federal Register, Vol. 86, No. 192 (October 7, 2021), pp. 56144–56180, https://www.govinfo.gov/content/ pkg/FR-2021-10-07/pdf/2021-21542.pdf (accessed March 18, 2023). 78. S. 624, Title X Abortion Provider Prohibition Act, 118th Congress, introduced March 2, 2023, https://www. congress.gov/118/bills/s624/BILLS-118s624is.pdf (accessed March 18, 2023). 79. 50 U.S. Code Chapter 55, https://www.law.cornell.edu/uscode/text/50/chapter-55 (accessed March 22, 2023). 80. 18 U.S. Code § 13, https://www.law.cornell.edu/uscode/text/18/13 (accessed March 18, 2023). 81. Bowen v. American Hospital Association, 476 U.S. 610 (1986), https://tile.loc.gov/storage-services/service/ll/ usrep/usrep476/usrep476610/usrep476610.pdf (accessed 22, 2023). 82. U.S. Department of Health and Human Services, Office of the Secretary, “Notification of Interpretation and Enforcement of Section 1557 of the Affordable Care Act and Title IX of the Education Amendments of 1972,” Federal Register, Vol. 86, No. 99 (May 25, 2021), pp. 27984–27985, https://www.govinfo.gov/content/pkg/FR- 2021-05-25/pdf/2021-10477.pdf (accessed March 18, 2023). 83. U.S. Department of Health and Human Services, Office for Civil Rights, “HHS Notice and Guidance on Gender Affirming Care, Civil Rights, and Patient Privacy,” March 2, 2022, https://www.hhs.gov/sites/default/files/hhs- ocr-notice-and-guidance-gender-affirming-care.pdf (accessed March 18, 2023). 84. Heckler v. Chaney, 420 U.S. 821 (1985), https://caselaw.findlaw.com/us-supreme-court/470/821.html (accessed March 18, 2022). 85. U.S. Department of Health and Human Services, Office for Civil Rights, “Guidance to Nation’s Retail Pharmacies: Obligations Under Federal Civil Rights Laws to Ensure Access to Comprehensive Reproductive Health Care Services,” content last reviewed July 14, 2022, https://www.hhs.gov/civil-rights/for-individuals/ special-topics/reproductive-healthcare/pharmacies-guidance/index.html (accessed March 18, 2023). 86. H.R. 3103, “Health Insurance and Portability and Accountability Act of 1996, Public Law No. 104-191, 104th Congress, August 21, 1996, https://www.congress.gov/104/plaws/publ191/PLAW-104publ191.pdf (accessed March 18, 2023). 87. U.S. Department of Human Services, “HIPAA Privacy Rule and Disclosures of Information Relating to Reproductive Health Care,” content last reviewed June 29, 2022, (accessed March 18, 2023). See also “Protecting the Privacy and Security of Your Health Information When Using Your Personal Cell Phone or Tablet,” content last reviewed June 29, 2022, https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/ cell-phone-hipaa/index.html (accessed March 18, 2023).

Department of Health and Human Services

Weak
Vector: 63%
Pages: 491-493AI Enhanced

AI Analysis:

"The SAFE KIDS Act focuses on restricting surrogacy for foreign adversarial nationals to protect American women and address national security, while the Project 2025 HHS section centers on abortion pill regulations, vaccine importation, fetal tissue research, and FDA reforms. Both share a pro-life framing of protecting women, but their substantive policies and mechanisms differ significantly."

Key themes:protection of womenpro-life valuesreproductive ethicsexploitation prevention

— 459 — Department of Health and Human Services pro-life states that are trying to protect women, girls, and unborn children from abortion. The FDA should therefore: l Reinstate earlier safety protocols for Mifeprex that were mostly eliminated in 2016 and apply these protocols to any generic version of mifepristone. A bare-minimum policy of limiting abortion pills to the pre-2016 policy of 49 days gestation, returning to the pre-2021 in-person dispensing requirement, and returning to requiring prescribers to report all serious adverse events, not just deaths, to the drug sponsor would increase women’s health and safety. l Address weaknesses in the current FAERS (FDA Adverse Events Reporting System). The Administration and policymakers should ensure that health care workers, particularly those in hospitals and emergency rooms, report abortion pill complications. Women who experience complications from abortion pills typically go to an emergency room, not to the abortion pill prescriber, so putting the onus of reporting on the prescriber who typically has no idea that a complication has occurred means that the FAERS is seriously undercounting adverse events. Submitting an adverse event to the database should be a quick and efficient process for busy health care practitioners. Currently, providers report that the process is difficult and convoluted. l Implement a policy of transparency about inspections of the abortion pill’s sponsors, Danco and GenBioPro, as well as facilities that manufacture the pills. The FDA should respond to congressional requests and Freedom of Information Act (FOIA) requests about inspections, compliance, and post-marketing safety in a timely manner. l Stop promoting or approving mail-order abortions in violation of long-standing federal laws that prohibit the mailing and interstate carriage of abortion drugs.16 Vaccine Importation. Thousands of Americans of faith and conscience wish to receive various childhood vaccinations for themselves and their families but are not allowed to receive vaccines that are derived through or tested on aborted fetal cells. For example, the chickenpox, Hepatitis, and MMR vaccines in the U.S. are all linked to abortion in this way. There are ethically derived alternatives abroad that have been used safely there for decades, but the FDA makes it exceedingly difficult for Americans to import them. In January 2021, the HHS Office for Civil Rights (OCR) and the FDA jointly announced that HHS was required by the Religious Freedom Restoration Act — 460 — Mandate for Leadership: The Conservative Promise (RFRA)17 to allow bulk importation by doctors of certain Japanese-made vaccines to accommodate religious needs of patients, but the Biden FDA unlawfully revoked this waiver. The FDA should restore the waiver to comply with RFRA and for the obvious public health benefits of increased childhood vaccination by families seek- ing ethically derived alternatives. To avoid future moral coercion of the sort experienced with the COVID-19 vac- cines, the FDA and NIH should require the development of drugs and biologics that are free from moral taint and switch to cell lines that are not derived from aborted fetal cell lines or aborted baby body parts. Conflicts of Interest. A 2018 report in Science found that more than two-thirds of FDA reviewers later ended up at the same companies whose products they had been reviewing while they were working for the government.18 This revolving door is one mechanism by which pharmaceutical companies capture the agencies that regulate them. The FDA should impose a lengthy cooling off period for reviewers, preventing them from working for companies they regulated. In 1997, the FDA relaxed regulations to permit broadcast drug advertisements, after which Big Pharma began routine direct-to-consumer advertising, making the United States and New Zealand the only countries where such practices are legal. Following the 1997 changes, pharma became the largest advertiser for all major media organizations. This buys considerable influence in the newsroom—whether media companies acknowledge this or not—and distorts independent reporting on public health issues. The FDA or Congress should regulate where and how paid advertising is used by pharmaceutical companies more stringently, especially on media outlets. NATIONAL INSTITUTES OF HEALTH (NIH) The National Institutes of Health (NIH) is the world’s largest biomedical research agency and is made up of 27 different components called Institutes and Centers. Despite its popular image as a benign science agency, NIH was respon- sible for paying for research in aborted baby body parts, human animal chimera experiments, and gain-of-function viral research that may have been responsible for COVID-19. Bioethics Reform. Research using fetal tissue obtained from elective abortions is immoral and obsolete. Research using human embryonic stem cells also involves the destruction of human life and should not be subsidized with taxpayer dollars. Good science and life-affirming, ethical research are not mutually exclusive. In fact, ethically derived sources such as discarded surgical tissue and adult stem cells (made pluripotent), not tissue obtained from elective abortions, have contributed the most successful treatments for a variety of ailments. Congress authorized HHS to choose not to fund extramural abortion-de- rived fetal tissue research that fails ethics advisory board review, and in 2019, the

Department of Health and Human Services

Weak
Vector: 63%
Pages: 488-490AI Enhanced

AI Analysis:

"The SAFE KIDS Act focuses on restricting surrogacy involving foreign adversarial nations to protect American women and address national security concerns, while the Project 2025 HHS section primarily addresses abortion data reporting, gender identity, FDA drug regulation, and abortion pills. There is only a tangential connection through a shared concern for protecting vulnerable populations (women) and federal oversight of health-related practices."

Key themes:women's protectionfederal oversightvulnerable populations

— 456 — Mandate for Leadership: The Conservative Promise abortion providers and whether better prenatal physical, mental, and social care improves infant outcomes and decreases abortion rates, especially among those who are most vulnerable. The Ensuring Accurate and Complete Abortion Data Reporting Act of 20239 would amend title XIX of the Social Security Act and Public Health Service Act to improve the CDC’s abortion reporting mechanisms by requiring states, as a condition of federal Medicaid payments for family planning services, to report streamlined variables in a timely manner. The CDC should immediately end its collection of data on gender identity, which legitimizes the unscientific notion that men can become women (and vice versa) and encourages the phenomenon of ever-multiplying subjective identities. FOOD AND DRUG ADMINISTRATION (FDA) The FDA’s mission includes ensuring the safety and efficacy of drugs, biological products, and medical devices. Federal Laws That Shield Big Pharma from Competition. Because generics generally cost far less than brand-name drugs, consumers begin to save money as soon as a generic product comes on the market. The vast majority are very afford- able with 93 percent of generic products costing $20 or less. Savings would be even higher under proposals that prevent brand-name man- ufacturers from slowing down or impeding the entrance of generic products into the marketplace. Specifically, the FDA should prohibit pharmaceutical companies from purposely sitting on their legally available right to be the first to sell generic versions of their drugs. Additionally, Congress should create legal remedies for generic companies to obtain samples of brand-name products for their generic development efforts and should prohibit meritless “citizen petitions” submitted by manufacturers to delay approval of a generic competitor.10 Approval Process for Laboratory-Developed or Modified Medical Tests. Learning from the failed early COVID-19 testing experience, Congress and the FDA should focus on reforming laws and regulations governing medical tests, especially with respect to laboratory-developed tests. Commercial tests are developed with the intention of being widely marketed, distributed, and used, while laboratory-developed tests are created with the intention of being used solely within one laboratory. A test developed by a lab in accordance with the protocols developed by another lab (non-commercial sharing) currently constitutes a “new” laboratory-developed test because the lab in which it will be used is different from the initial developing lab. To encourage interlab- oratory collaboration and discourage duplicative test creation (and associated regulatory and logistical burdens), the FDA should introduce mechanisms through which laboratory-developed tests can easily be shared with other laboratories with- out the current regulatory burdens.11 — 457 — Department of Health and Human Services The “laboratory-developed tests” category currently encompasses a range of possible tests, many of which would be characterized more appropriately as “lab- oratory-modified tests” because they are not truly novel tests but rather modified versions of existing tests. To avoid stifling innovation and access to medical care, the applicable statutes and regulations should be revised to facilitate greater access to such modified tests.12 Finally, the FDA has long held that it has regulatory authority over such tests, while others have argued that they should be considered clinical services regulated by the Centers for Medicare and Medicaid Services (CMS). The FDA currently has regulatory authority over in vitro diagnostics, and under the Clinical Lab- oratory Improvement Amendments (CLIA),13 the CMS ensures that labs meet analytical validity standards for test methods. Congress, the FDA, and the CMS need to clarify and disentangle overlapping authorities over tests to eliminate regulatory confusion.14 Drug Shortages. The very thin profit margins and the regulatory burdens associated with generic drug manufacturing discourage inventory and capacity investments by manufacturers and contribute to drug shortages. HHS and the FDA should encourage more dependable generic drug manufacturing. The FDA should expand its current pass/fail approach to drug facility inspec- tions into a graded system that recognizes manufacturers that exceed minimum standards by investing in improving production reliability. The FDA should also add facility codes to drug packaging and construct a searchable database that cross-references product codes and facility codes. That would enable wholesalers and pharmacy benefit managers to identify and preference drugs manufactured at more reliable facilities, thus encouraging generic drug manufacturers to compete on reliability as well as on price. For its part, HHS should exempt multi-source generic drugs from requirements to pay rebates to Medicaid and other federally funded health programs, as those provisions penalize new investments in expanding manufacturing capacity when supply is unable to meet demand.15 Additionally, FDA and NIH should promote efficacy trials of new applications for generic drugs, which might include NIH fund- ing such trials or conducting its own. Abortion Pills. Abortion pills pose the single greatest threat to unborn chil- dren in a post-Roe world. The rate of chemical abortion in the U.S. has increased by more than 150 percent in the past decade; more than half of annual abortions in the U.S. are chemical rather than surgical. The abortion pill regimen is typically a two-part process. The first pill, mifepris- tone, causes the death of the unborn child by cutting off the hormone progesterone, which is required to sustain a pregnancy. The second pill, misoprostol, causes con- tractions to induce a delivery of the dead child and uterine contents, usually into a toilet at home. The abortion-pill regimen is currently approved for up to 70 days

Showing 3 of 5 policy matches

About These Correlations

Policy matches are calculated using a hybrid approach: initial candidates are found using semantic similarity between bill summaries and Project 2025 policy text, then an AI model (Llama 3.1 70B) provides detailed alignment ratings and analysis. Ratings range from 1 (minimal alignment) to 5 (very strong alignment). This analysis does not imply direct causation or intent.

Full Policy Text

Related Bills